Rosacea Radiofrequency Microneedling

Description

There are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for combination treatment of radiofrequency microneedling with the 532 nm KTP laser, and (3) identify potential novel therapeutic strategies for the treatment of rosacea.

Conditions

Rosacea, Papulopustular, Rosacea, Erythematotelangiectatic

Talk to us

Study Overview

On this page

Study Details

Study overview

There are 3 main objectives of this proposal as follows: (1) to assess the efficacy of radiofrequency microneedling in the treatment of erythematotelangiectatic and or papulopustular rosacea, (2) to determine the potential for combination treatment of radiofrequency microneedling with the 532 nm KTP laser, and (3) identify potential novel therapeutic strategies for the treatment of rosacea.

Split-Face Comparison of 532nm Potassium Titanyl Phosphate (KTP) Laser Treatment Versus Radiofrequency Microneedling in Combination With 532 KTP Laser for Erythematotelangiectatic or Papulopustular Rosacea

Rosacea Radiofrequency Microneedling

Condition
Rosacea, Papulopustular
Intervention / Treatment

-

Contacts and Locations

Miami Beach

University of Miami Dermatology Miami Beach Clinic, Miami Beach, Florida, United States, 33128

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male or female adult (\>18yo) subjects in general good health
  • 2. Clinical and/or histologic diagnosis of erythematotelangiectatic or papulopustular rosacea.
  • 3. Subject is able to understand and sign informed consent
  • 4. Subject is able to complete the study and comply with study procedures
  • 1. Patients currently utilizing oxymetazoline or brimonidine.
  • 2. Presence of dermatoses that might interfere with diagnosis as determined by a study investigator
  • 3. Presence of extreme light sensitivity, or conditions pre-disposing to light sensitivity such as but not limited to xeroderma pigmentosum
  • 4. Any significant medical condition that may prevent the patient from participating in the study according to the investigator's assessment
  • 5. History of poor wound healing or blood-clotting abnormality
  • 6. History of keloid formation or hypertrophic scarring
  • 7. Hypersensitivity or contraindication to local anesthetics as determined by the principal investigator or other medical professional.
  • 8. Prisoners

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Miami,

Ariel Eber, MD, PRINCIPAL_INVESTIGATOR, University of Miami

Study Record Dates

2026-04-01